Does Amerigroup Cover Lantus?

How Amerigroup Formularies Handle Lantus

Amerigroup, a subsidiary of Elevance Health (formerly Anthem), operates Medicaid managed care, Medicare Advantage, and Marketplace plans across more than 20 states. Each state contract produces a separate formulary, so a member in Georgia may face different tier placement and cost-sharing than a member in Texas or New Jersey.

Medicaid Managed Care Plans

Most Amerigroup Medicaid formularies list Lantus as a covered brand insulin. Because Medicaid programs negotiate supplemental rebates with manufacturers, Lantus often lands on a preferred brand tier with nominal copays. In states where federal Medicaid rules prohibit cost-sharing for certain populations (children, pregnant individuals, or those below the federal poverty level), the copay drops to zero 1. For adults above 150% of the federal poverty level, copays typically range from $1 to $3 per fill.

Marketplace and Exchange Plans

Amerigroup Marketplace plans (sold under the Anthem or Wellpoint brand in some states) use a different formulary structure. Lantus often appears on Tier 3 (non-preferred brand), which means the copay can range from $50 to $150 per 30-day supply before the deductible is met. The Inflation Reduction Act's $35 monthly insulin copay cap, signed into law in 2022 and fully implemented for commercial plans starting January 2025, applies to most Amerigroup Marketplace members 2.

Medicare Advantage (Dual-Eligible)

For dual-eligible members enrolled in Amerigroup Medicare-Medicaid plans, insulin copays are capped at $35 per month per covered insulin product under Part D provisions. Lantus is generally listed on Medicare Part D formularies as a Tier 2 or Tier 3 drug 3.

Understanding the $35 Insulin Copay Cap

The $35 monthly insulin copay cap changed the cost equation for millions of Americans. Before this cap took effect, roughly 1.3 million Medicare Part D enrollees paid more than $35 per month for insulin, with some spending over $100 per fill 4. The cap now applies to all Medicare plans and, as of 2025, to most commercial and Marketplace plans.

How the Cap Works in Practice

The cap applies at the pharmacy counter. If your Amerigroup plan lists Lantus on its formulary and you have an active prescription, you will not pay more than $35 for a 30-day supply regardless of whether you have met your deductible. This is a per-insulin cap, meaning if you use both Lantus and a rapid-acting insulin like NovoLog, each carries its own $35 maximum.

Exceptions and Gaps

The cap does not apply to insulin purchased outside of your plan's pharmacy network. If you fill a Lantus prescription at an out-of-network pharmacy, standard out-of-network cost-sharing applies. The cap also does not apply to insulin pump supplies or to insulin purchased through manufacturer discount programs that operate outside of insurance billing.

Prior Authorization and Step Therapy Requirements

Not every Amerigroup plan covers Lantus without conditions. Some formularies designate a biosimilar insulin glargine as the preferred product and require prior authorization (PA) or step therapy before approving brand Lantus.

What Triggers a PA for Lantus

A prior authorization request is typically triggered when: your plan prefers a biosimilar alternative and you have not tried it first; the prescribed quantity exceeds the plan's monthly limit (usually 10 mL or 15 mL for vials, or one box of five KwikPens); or your prescriber writes for a non-standard dosing regimen. PA turnaround time is generally 24 to 72 hours for standard requests and 24 hours for urgent requests 5.

Step Therapy Protocols

Some Amerigroup formularies require step therapy, meaning you must try and fail a preferred biosimilar insulin glargine (such as Semglee or Rezvoglar) before the plan will cover brand Lantus. "Fail" can mean documented clinical inefficacy, an adverse reaction, or a contraindication to the biosimilar's inactive ingredients.

The American Diabetes Association's 2024 Standards of Care notes that insulin glargine biosimilars have demonstrated equivalent glycemic control to the reference product in multiple phase III trials 6. From a clinical standpoint, switching between the reference Lantus and a biosimilar does not typically affect HbA1c outcomes or hypoglycemia rates.

Lantus Biosimilars Covered by Amerigroup

Biosimilar insulin glargine products have reshaped formulary placement across Medicaid and commercial plans. Two FDA-approved biosimilars are widely available.

Semglee (Insulin Glargine-yfgn)

Semglee, manufactured by Mylan (a Viatris subsidiary), was the first interchangeable biosimilar insulin approved by the FDA in July 2021 7. Its interchangeable designation means pharmacists in most states can substitute it for Lantus at the pharmacy counter without contacting the prescriber. Many Amerigroup Medicaid plans list Semglee as the preferred insulin glargine product.

Rezvoglar (Insulin Glargine-aglr)

Rezvoglar, manufactured by Eli Lilly, received FDA approval in December 2021. While not designated as interchangeable (it holds biosimilar-only status), it is therapeutically equivalent and appears on several Amerigroup formularies as a Tier 2 preferred brand.

In the ELEMENT 1 trial (N=535), insulin glargine biosimilar LY2963016 (the molecule behind Rezvoglar) demonstrated non-inferiority to Lantus in HbA1c reduction over 24 weeks in patients with type 1 diabetes, with a mean HbA1c change of -0.35% vs. -0.46% in the Lantus arm 8.

How to Check Your Specific Amerigroup Formulary

Because Amerigroup operates under different state contracts, there is no single national formulary. Checking your own plan's drug list takes a few steps.

Online Formulary Lookup

Visit the Amerigroup website for your state (e.g., amerigroup.com/ga for Georgia) and manage to the "Find a Drug" or "Formulary" section. Enter "insulin glargine" or "Lantus" to see the tier, any PA or quantity limit codes, and preferred alternatives. Formularies are updated quarterly, so check the effective date on the document.

Call Member Services

The phone number on the back of your Amerigroup ID card connects you to member services. Ask specifically: "Is Lantus on my formulary, what tier is it on, does it require prior authorization, and is there a preferred alternative?" Write down the reference number for the call.

Ask Your Pharmacist

Pharmacists can run a real-time eligibility check through your plan's pharmacy benefit manager (PBM). This check shows the exact copay, any PA flags, and whether a biosimilar would process at a lower tier. This is often the fastest way to get a definitive answer.

Cost Comparison: Lantus vs. Biosimilars on Amerigroup

The wholesale acquisition cost (WAC) of Lantus has been listed at approximately $283 per vial (10 mL, 100 units/mL) and $425 per box of five KwikPens 9. Biosimilar alternatives carry lower list prices.

Semglee's WAC runs roughly 65% lower than brand Lantus, at around $100 per vial. For Amerigroup Medicaid members, this price difference may not affect out-of-pocket costs (which are already near $0), but for Marketplace members, a lower-tier biosimilar could mean a $25 copay instead of a $50 to $75 copay, even with the $35 cap in place for insulin-specific cost-sharing.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "The availability of biosimilar insulins is a meaningful step toward reducing the financial burden of diabetes management, particularly for the uninsured and underinsured" 10.

What Happens If Amerigroup Denies Lantus Coverage

A denial is not the end of the process. Amerigroup members have the right to appeal any formulary coverage decision through a structured process.

Internal Appeal

File an internal appeal within 60 days of the denial notice. Your prescriber should submit a letter of medical necessity explaining why brand Lantus is required instead of a biosimilar. Common reasons include documented adverse reactions to biosimilar excipients, dose titration instability after switching, or patient-specific factors like needle phobia that makes a specific pen device necessary.

External Review

If the internal appeal is denied, Medicaid members can request a state fair hearing. Marketplace members can request an independent external review through their state's insurance department. The external review decision is binding on the plan 11.

Manufacturer Assistance Programs

Sanofi, the manufacturer of Lantus, offers the Valyou Savings Program for uninsured patients and copay cards for commercially insured patients. The Valyou program prices Lantus at $78.90 per vial for eligible patients without insurance 12. These programs run outside of insurance and do not count toward deductibles or out-of-pocket maximums.

Clinical Context: Why Lantus Remains Widely Prescribed

Lantus (insulin glargine U-100) was approved by the FDA in 2000 and has become the most prescribed basal insulin globally. Its 24-hour duration of action and relatively flat pharmacokinetic profile allow once-daily dosing for both type 1 and type 2 diabetes 13.

Glycemic Outcomes in Major Trials

In the ORIGIN trial (N=12,537), insulin glargine used as early basal insulin therapy in patients with dysglycemia maintained median HbA1c at 6.2% over a median follow-up of 6.2 years, with a modest weight gain of 1.6 kg compared to standard care 14. The trial also demonstrated cardiovascular neutrality, an important safety finding for a medication used long-term.

Hypoglycemia Profile

The EDITION 1 trial (N=807) comparing Lantus to Toujeo (insulin glargine U-300) found that the annualized rate of confirmed nocturnal hypoglycemia (blood glucose <54 mg/dL) was 36% lower with Toujeo, though overall glycemic control was equivalent 15. For patients on Amerigroup plans where Toujeo is also covered, this may factor into prescribing decisions.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "For many patients with type 2 diabetes, basal insulin glargine remains the backbone of injectable therapy, and the arrival of biosimilars has made it more accessible than at any point in its history" 16.

Tips for Reducing Your Lantus Costs on Amerigroup

Even with insurance coverage, there are practical steps to minimize out-of-pocket spending on Lantus or its biosimilars.

Use Preferred Pharmacies

Amerigroup contracts with preferred pharmacy networks that offer lower copays. Walmart, CVS, and certain independent pharmacies may carry preferred status depending on your state. Check your plan's pharmacy directory before filling.

Request 90-Day Fills

Many Amerigroup plans offer 90-day supplies through mail-order pharmacies at a lower per-fill copay than three separate 30-day fills. For a stable basal insulin regimen, this can reduce both cost and pharmacy visits.

Switch to a Biosimilar If Clinically Appropriate

If your prescriber agrees that a biosimilar insulin glargine is clinically appropriate, switching from brand Lantus to Semglee or Rezvoglar may move your prescription to a lower formulary tier. The ADA's 2024 Standards of Care support biosimilar use as clinically equivalent to reference insulin products 6.

Amerigroup members filling Lantus should confirm their plan's current formulary tier, ask about biosimilar alternatives, and verify that the $35 insulin copay cap applies to their specific plan type before their next refill.